In Brief

FDA softens disclaimer for green tea QHC; Formulife/Purus covers spectrum of violations; NAD refers Schick case to FTC; Genomma drops Prestige Brands board bid.

FDA gives sunscreen makers an eleventh-hour extension to comply with new labeling and effectiveness testing requirements. The agency pushed back the deadline by six months for sunscreen products to undergo broad spectrum testing and amend label claims to reflect the test results. Firms now must test and revise packaging by Dec. 17, 2012, for all products with annual sales of $25,000 and up, and by Dec. 17, 2013, for other products, according to a notice in the May 11 Federal Register. FDA extended the deadline after the Consumer Healthcare Products Association and the Personal Care Products Council argued broad spectrum testing for all the sunscreen products would require at least 10 months due to the limited capacity of testing facilities and that complex label redesigns, such as on glass or plastic containers, would take longer than the one year the agency originally granted. Without a delay, the trade groups also argued, firms might pull their products from the market until they complied, which would result in a sunscreen shortage Also see "Industry Needs More Time To Comply With Sunscreen Testing, Labeling Rule" - Pink Sheet, 29 August, 2011..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

CSL Makes Landmark National-Level Pay-For-Performance Deal In Germany For Hemgenix

 

A blanket pricing agreement CSL has formed with German health insurers for the gene therapy, Hemgenix, makes the cost of treatment budget-neutral compared to traditional treatment.

New Carbon Monitoring Initiative Could Help Future Proof Clinical Research

 

A new European initiative will help trial sponsors better understand whether digitization and decentralized clinical trials of drugs generate less carbon than traditional methods.

Major Analysis To Help MHRA Fill Gaps In UK Clinical Trials Landscape

 
• By 

A first-of-its-kind review of clinical trial applications submitted to the UK medicines regulator, the MHRA, shows there is a concentration of research in certain disease areas and identifies opportunities to enhance the representation of specific patient groups.

New Medicines Pricing Proposals Would Mean More Uncertainty For Spanish Supply Chains

 

Proposals to reform Spain’s reference pricing system are out of whack with the national pharmaceutical strategy published in December, six industry associations have warned.

More from Geography

Kennedy’s Comments On Novavax Delay Scientifically, Legally Inaccurate, Experts Say

 

The HHS Secretary publicly acknowledged the unusual delay of Novavax's COVID-19 vaccine licensure, but his justification was neither scientifically accurate nor legally justifiable, experts said.

New Carbon Monitoring Initiative Could Help Future Proof Clinical Research

 

A new European initiative will help trial sponsors better understand whether digitization and decentralized clinical trials of drugs generate less carbon than traditional methods.

Major Analysis To Help MHRA Fill Gaps In UK Clinical Trials Landscape

 
• By 

A first-of-its-kind review of clinical trial applications submitted to the UK medicines regulator, the MHRA, shows there is a concentration of research in certain disease areas and identifies opportunities to enhance the representation of specific patient groups.